PR Newswire Clinical TrialsOriginal article
MOYOM treibt die regenerative Ästhetik in Europa durch die EU-MDR-Zertifizierung von APHRANEL® sowie eine strategische wissenschaftliche Zusammenarbeit mit Expert2Expert voran
RegulatoryapprovedAPHRANEL®Positive
AI Analysis
Summary
MOYOM announced EU-MDR certification for APHRANEL® and a strategic scientific collaboration with Expert2Expert to advance regenerative aesthetics in Europe.
Outcome Details
EU-MDR certification obtained for APHRANEL®
Importance:6/10
Sentiment:
0.80
EU-MDRmedical deviceregulatory approvalEurope expansionaesthetic medicinepartnership
Read the original article
Published by PR Newswire Clinical Trials on August 3, 2026 3:05 AM